HIV	B:C2917373
-	I:C2917373
1	I:C2917373
integrase	I:C2917373
inhibitor	I:C2917373
resistance	O
among	O
treatment	O
naïve	O
patients	O
in	O
the	O
West	O
of	O
Scotland	O
Transmitted	O
integrase	O
inhibitor	I:C0376601
resistance	O
is	O
rare	O
,	O
with	O
only	O
a	O
small	O
number	O
of	O
cases	O
reported	O
world	O
-	O
wide	O
to	O
date	O
.	O

HIV	O
-	I:C2917373
1	I:C2917373
integrase	I:C2917373
inhibitor	I:C2917373
resistance	B:C0013203
among	O
treatment	O
naïve	O
patients	O
in	O
the	O
West	O
of	O
Scotland	O
Transmitted	O
integrase	O
inhibitor	I:C0376601
resistance	O
is	O
rare	O
,	O
with	O
only	O
a	O
small	O
number	O
of	O
cases	O
reported	O
world	O
-	O
wide	O
to	O
date	O
.	O

HIV	O
-	I:C2917373
1	I:C2917373
integrase	I:C2917373
inhibitor	I:C2917373
resistance	O
among	O
treatment	B:C0087111
naïve	O
patients	O
in	O
the	O
West	O
of	O
Scotland	O
Transmitted	O
integrase	O
inhibitor	I:C0376601
resistance	O
is	O
rare	O
,	O
with	O
only	O
a	O
small	O
number	O
of	O
cases	O
reported	O
world	O
-	O
wide	O
to	O
date	O
.	O

HIV	O
-	I:C2917373
1	I:C2917373
integrase	I:C2917373
inhibitor	I:C2917373
resistance	O
among	O
treatment	O
naïve	O
patients	O
in	O
the	O
West	B:C1705493
of	O
Scotland	O
Transmitted	O
integrase	O
inhibitor	I:C0376601
resistance	O
is	O
rare	O
,	O
with	O
only	O
a	O
small	O
number	O
of	O
cases	O
reported	O
world	O
-	O
wide	O
to	O
date	O
.	O

HIV	O
-	I:C2917373
1	I:C2917373
integrase	I:C2917373
inhibitor	I:C2917373
resistance	O
among	O
treatment	O
naïve	O
patients	O
in	O
the	O
West	O
of	O
Scotland	B:C0036453
Transmitted	O
integrase	O
inhibitor	I:C0376601
resistance	O
is	O
rare	O
,	O
with	O
only	O
a	O
small	O
number	O
of	O
cases	O
reported	O
world	O
-	O
wide	O
to	O
date	O
.	O

HIV	O
-	I:C2917373
1	I:C2917373
integrase	I:C2917373
inhibitor	I:C2917373
resistance	O
among	O
treatment	O
naïve	O
patients	O
in	O
the	O
West	O
of	O
Scotland	O
Transmitted	O
integrase	B:C0376601
inhibitor	I:C0376601
resistance	O
is	O
rare	O
,	O
with	O
only	O
a	O
small	O
number	O
of	O
cases	O
reported	O
world	O
-	O
wide	O
to	O
date	O
.	O

HIV	O
-	I:C2917373
1	I:C2917373
integrase	I:C2917373
inhibitor	I:C2917373
resistance	O
among	O
treatment	O
naïve	O
patients	O
in	O
the	O
West	O
of	O
Scotland	O
Transmitted	O
integrase	O
inhibitor	I:C0376601
resistance	B:C0013203
is	O
rare	O
,	O
with	O
only	O
a	O
small	O
number	O
of	O
cases	O
reported	O
world	O
-	O
wide	O
to	O
date	O
.	O

HIV	O
-	I:C2917373
1	I:C2917373
integrase	I:C2917373
inhibitor	I:C2917373
resistance	O
among	O
treatment	O
naïve	O
patients	O
in	O
the	O
West	O
of	O
Scotland	O
Transmitted	O
integrase	O
inhibitor	I:C0376601
resistance	O
is	O
rare	O
,	O
with	O
only	O
a	O
small	O
number	O
of	O
cases	O
reported	B:C0684224
world	O
-	O
wide	O
to	O
date	O
.	O

The	O
aim	O
of	O
this	O
study	B:C2603343
was	O
to	O
assess	O
whether	O
transmitted	O
integrase	O
inhibitor	I:C0376601
resistance	O
has	O
occurred	O
in	O
Scotland	O
and	O
if	O
so	O
,	O
could	O
there	O
be	O
a	O
case	O
for	O
performing	O
genotypic	O
integrase	I:C0877124
resistance	I:C0877124
testing	I:C0877124
at	O
baseline	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
whether	O
transmitted	O
integrase	B:C0376601
inhibitor	I:C0376601
resistance	O
has	O
occurred	O
in	O
Scotland	O
and	O
if	O
so	O
,	O
could	O
there	O
be	O
a	O
case	O
for	O
performing	O
genotypic	O
integrase	I:C0877124
resistance	I:C0877124
testing	I:C0877124
at	O
baseline	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
whether	O
transmitted	O
integrase	O
inhibitor	I:C0376601
resistance	B:C0013203
has	O
occurred	O
in	O
Scotland	O
and	O
if	O
so	O
,	O
could	O
there	O
be	O
a	O
case	O
for	O
performing	O
genotypic	O
integrase	I:C0877124
resistance	I:C0877124
testing	I:C0877124
at	O
baseline	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
whether	O
transmitted	O
integrase	O
inhibitor	I:C0376601
resistance	O
has	O
occurred	O
in	O
Scotland	B:C0036453
and	O
if	O
so	O
,	O
could	O
there	O
be	O
a	O
case	O
for	O
performing	O
genotypic	O
integrase	I:C0877124
resistance	I:C0877124
testing	I:C0877124
at	O
baseline	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
whether	O
transmitted	O
integrase	O
inhibitor	I:C0376601
resistance	O
has	O
occurred	O
in	O
Scotland	O
and	O
if	O
so	O
,	O
could	O
there	O
be	O
a	O
case	O
for	O
performing	O
genotypic	B:C0877124
integrase	I:C0877124
resistance	I:C0877124
testing	I:C0877124
at	O
baseline	O
.	O

The	O
study	B:C2348561
population	I:C2348561
consisted	O
of	O
106	O
treatment	O
naïve	O
,	O
newly	O
diagnosed	O
,	O
HIV	O
positive	I:C0019699
patients	O
.	O

The	O
study	O
population	I:C2348561
consisted	O
of	O
106	O
treatment	B:C0087111
naïve	O
,	O
newly	O
diagnosed	O
,	O
HIV	O
positive	I:C0019699
patients	O
.	O

The	O
study	O
population	I:C2348561
consisted	O
of	O
106	O
treatment	O
naïve	O
,	O
newly	O
diagnosed	O
,	O
HIV	B:C0019699
positive	I:C0019699
patients	O
.	O

The	O
patient	B:C1550655
samples	I:C1550655
were	O
collected	O
between	O
October	O
2015	O
and	O
March	O
2016	O
at	O
the	O
time	O
of	O
HIV	O
diagnosis	O
and	O
prior	O
to	O
initiation	O
of	O
anti-retroviral	O
therapy	I:C1963724
.	O

The	O
patient	O
samples	I:C1550655
were	O
collected	O
between	O
October	O
2015	O
and	O
March	O
2016	O
at	O
the	O
time	O
of	O
HIV	O
diagnosis	O
and	O
prior	O
to	O
initiation	O
of	O
anti-retroviral	B:C1963724
therapy	I:C1963724
.	O

The	O
integrase	O
region	O
was	O
amplified	B:C0017256
and	O
sequenced	O
.	O

The	O
integrase	O
region	O
was	O
amplified	O
and	O
sequenced	B:C1294197
.	O

We	O
detected	B:C0442726
integrase	O
inhibitor	I:C0376601
resistance	O
(	O
T66I	O
/T	O
)	O
at	O
baseline	O
in	O
one	O
patient	O
sample	I:C1550655
.	O

We	O
detected	O
integrase	B:C0376601
inhibitor	I:C0376601
resistance	O
(	O
T66I	O
/T	O
)	O
at	O
baseline	O
in	O
one	O
patient	O
sample	I:C1550655
.	O

We	O
detected	O
integrase	O
inhibitor	I:C0376601
resistance	B:C0013203
(	O
T66I	O
/T	O
)	O
at	O
baseline	O
in	O
one	O
patient	O
sample	I:C1550655
.	O

We	O
detected	O
integrase	O
inhibitor	I:C0376601
resistance	O
(	O
T66I	O
/T	O
)	O
at	O
baseline	O
in	O
one	O
patient	B:C1550655
sample	I:C1550655
.	O

This	O
is	O
a	O
non-polymorphic	B:C0026882
mutation	I:C0026882
seen	O
in	O
patients	O
receiving	O
elvitegravir	O
which	O
confers	O
high	O
-	O
level	O
resistance	O
to	O
elvitegravir	O
and	O
intermediate	O
resistance	O
to	O
raltegravir	O
.	O

This	O
is	O
a	O
non-polymorphic	O
mutation	I:C0026882
seen	O
in	O
patients	O
receiving	O
elvitegravir	B:C2606637
which	O
confers	O
high	O
-	O
level	O
resistance	O
to	O
elvitegravir	O
and	O
intermediate	O
resistance	O
to	O
raltegravir	O
.	O

This	O
is	O
a	O
non-polymorphic	O
mutation	I:C0026882
seen	O
in	O
patients	O
receiving	O
elvitegravir	O
which	O
confers	O
high	O
-	O
level	O
resistance	B:C0013203
to	O
elvitegravir	O
and	O
intermediate	O
resistance	O
to	O
raltegravir	O
.	O

This	O
is	O
a	O
non-polymorphic	O
mutation	I:C0026882
seen	O
in	O
patients	O
receiving	O
elvitegravir	O
which	O
confers	O
high	O
-	O
level	O
resistance	O
to	O
elvitegravir	B:C2606637
and	O
intermediate	O
resistance	O
to	O
raltegravir	O
.	O

This	O
is	O
a	O
non-polymorphic	O
mutation	I:C0026882
seen	O
in	O
patients	O
receiving	O
elvitegravir	O
which	O
confers	O
high	O
-	O
level	O
resistance	O
to	O
elvitegravir	O
and	O
intermediate	B:C0205103
resistance	O
to	O
raltegravir	O
.	O

This	O
is	O
a	O
non-polymorphic	O
mutation	I:C0026882
seen	O
in	O
patients	O
receiving	O
elvitegravir	O
which	O
confers	O
high	O
-	O
level	O
resistance	O
to	O
elvitegravir	O
and	O
intermediate	O
resistance	B:C0013203
to	O
raltegravir	O
.	O

This	O
is	O
a	O
non-polymorphic	O
mutation	I:C0026882
seen	O
in	O
patients	O
receiving	O
elvitegravir	O
which	O
confers	O
high	O
-	O
level	O
resistance	O
to	O
elvitegravir	O
and	O
intermediate	O
resistance	O
to	O
raltegravir	B:C1871526
.	O

A	O
further	O
10	O
patients	O
had	O
accessory	B:C0026882
mutations	I:C0026882
which	O
have	O
minimal	O
or	O
no	O
effect	O
on	O
susceptibility	O
to	O
integrase	O
inhibitors	I:C0376601
.	O

A	O
further	O
10	O
patients	O
had	O
accessory	O
mutations	I:C0026882
which	O
have	O
minimal	O
or	O
no	O
effect	O
on	O
susceptibility	B:C0012655
to	O
integrase	O
inhibitors	I:C0376601
.	O

A	O
further	O
10	O
patients	O
had	O
accessory	O
mutations	I:C0026882
which	O
have	O
minimal	O
or	O
no	O
effect	O
on	O
susceptibility	O
to	O
integrase	B:C0376601
inhibitors	I:C0376601
.	O

Transmitted	O
integrase	B:C0376601
inhibitor	I:C0376601
resistance	O
remains	O
rare	O
.	O

Transmitted	O
integrase	O
inhibitor	I:C0376601
resistance	B:C0013203
remains	O
rare	O
.	O

The	O
results	O
of	O
the	O
present	O
study	B:C2603343
do	O
not	O
support	O
performing	O
integrase	O
resistance	O
testing	O
at	O
baseline	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
do	O
not	O
support	O
performing	O
integrase	B:C0376601
resistance	O
testing	O
at	O
baseline	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
do	O
not	O
support	O
performing	O
integrase	O
resistance	B:C0013203
testing	O
at	O
baseline	O
.	O

